A US health conglomerate unpicks itself, and one malaria drug gets three cure rates

CVS Health will split in two, separating its insurer and pharmacy-benefit business from its pharmacies and walk-in clinics. Democrats won both chambers of the US Congress, and the law that funds the FDA's drug reviews is heading for a committee likely led by one of the programme's critics. A randomised trial gave pregnant and postpartum people a year of access to a generative AI health chatbot, and anxiety and depression did not change. WHO cleared trials of two vaccines built for the Bundibugyo Ebola strain, with results expected early next year. PCR correction, the genotyping step that decides whether a malaria drug failed or a mosquito bit again, is today's medicine concept.

Connecting the dots

The young came because the stars would not. EMBL, Europe's molecular biology laboratory, was meant to gather great names, but "it soon became apparent the institute could not attract people away from long-term tenure track professorships", and its historian concludes: "Much of the strength turned out to be in establishing networks rather than monolithic ‘big science’," (EMBL). The tribute to the embryologist Marta Shahbazi, below, records the same form two generations later: "She co-founded a network of junior group leaders studying early mammalian development to pool ideas and share unpublished data." (MRC LMB).

What a claim of machine research is checked against. This week's Nature carries "An AI-native experimental laboratory for autonomous biomolecular operations", and arXiv carries "We Ran a Research Sprint With AI. The AI Worked. The Research Didn't". Three company claims today each pick a different check: a solved structure (Anthropic), the experiments a drug committee actually asked for (Edison), a shared neoantigen benchmark (Halmos). A post-hoc analysis inside a pre-registered test, on scheduling and edge-computing problems, adds that "the fastest path to better discovery is widening the pool, not tightening the gate" (arXiv). Speculation: if that travels to biology, what an agent is allowed to propose may matter more than how hard its results are checked.

The clock nobody owns. On the night the clocks changed, biomedical technicians compared notes: "It can cause a problem with the timestamps of treatment if its mismatched to the charting software like epic." (r/BMET). A CPAP user reports "events taking place hours after I was already awake with the mask off", with the cause unsettled (r/cpap). And a French hobbyist's survey of public time servers, which says nothing about hospitals, finds nearly 14% of them depending on nine machines (LinuxFr).

How far a failure travels. Today's book says that once specialists build, failures "have to be several times reported and described" before anyone repairs them (excerpts, Are.na). A 2022 English investigation describes that distance in sterile services: "There is no requirement to report issues nationally relating to incorrectly decontaminated surgical instruments." (HSSIB).

Methods

Where single-cell foundation models beat simple baselines, and where they tie

A preprint compares five foundation models, large models pretrained on many cell profiles, with simple baselines on annotation, perturbation and gene-regulation tasks.

"FMs were most useful when labels had to be transferred across species: from human to mouse lung," — bioRxiv

"Within a species, FM embeddings annotated cells as accurately as principal components." — same

Why it matters: it tells anyone choosing an embedding when the heavier model is likely to earn its compute. On patient organoids, the authors say the design "did not yet separate methods from differences between clones and donors".

Clinical trials

A year with a maternal health chatbot, and no change in anxiety or depression

Four hundred pregnant or postpartum participants from racial or ethnic minoritized groups across the US were randomised, against an active control of monthly children's books.

"access to a generative artificial intelligence maternal health chatbot did not improve maternal anxiety or depression" — JAMA Network Open, PubMed

Why it matters: this is a randomised test of a patient-facing generative tool, with a year of follow-up and patient outcomes as primary endpoints.

Plozasiran cut triglycerides and acute pancreatitis

"The rates of acute pancreatitis were 1 per 100 patient-years with plozasiran and 5 per 100 patient-years with placebo." — NEJM, PubMed

Why it matters: two trials in 757 adults with severe hypertriglyceridemia, very high blood fats, report triglycerides down "79% and 81%" at a year, plus this clinical event pooled as a secondary endpoint. Arrowhead funded them.

Complement inhibition missed in a transplant complication

In thrombotic microangiopathy after stem cell transplant, where small vessels clot and tissue is damaged, event-free survival over 26 weeks was about 56% with ravulizumab and 48% with placebo: hazard ratio 0.879, confidence interval 0.526 to 1.467 (ClinicalTrials.gov).

Why it matters: a double-blind phase 3 trial in 148 patients has now posted its result for complement inhibition in this complication.

A pocket colposcope in Kisumu, and an authors' claim to read closely

HPV-positive women living with HIV at six Kenyan clinics were triaged with a low-cost handheld colposcope or by naked-eye inspection.

"The Pocket colposcope detected more treatable disease and reduced overtreatment." — British Journal of Cancer, PubMed

Why it matters: the same abstract reports "a non-significant higher positive predictive value (37.5% vs 20.6%)", and two authors are tied to the foundation that commercialised the device.

Emrusolmin stopped in multiple system atrophy

"No safety concerns arose from the interim review." — Clinical Trials Arena

Why it matters: the independent committee's review "met the predefined futility criterion", ending a placebo-controlled phase 2 trial in this rare neurodegenerative disease. No effect size was released.

Elsewhere: 177Lu-PSMA-617, a radioactive drug that seeks prostate cancer cells, delayed radiographic progression in hormone-sensitive metastatic disease, hazard ratio 0.72 (ClinicalTrials.gov).

Hospitals

Korea: a psychiatrist attacked mid-consultation

"This patient had no appointment at the time and reportedly burst into the consulting room while Professor A was seeing another patient." (translated from Korean; original: "이 환자는 당시 진료가 예정돼 있지 않았으며, A교수가 다른 환자를 진료하던 중 갑자기 진료실에 난입한 것으로 전해졌다.") — Korean Doctors' Weekly

Why it matters: the residents' council says repeated violence, despite legally mandated security, shows the system "is not working effectively on the ground" (translated; original "제도가 현장에서 실효적으로 작동하지 못하고 있음을") (same). It wants inspections to test whether staff can escape and get help.

Cyber incidents, from the records to the cold room

"the incident has disrupted pre-authorizations, and some appointments and elective procedures have had to be rescheduled" — HIPAA Journal

That is University Hospitals, a US health system, two weeks on. In France the blood service says (translated from Italian) "It was our refrigeration-equipment supplier that suffered a cyber incident yesterday"; original: "È stato il nostro fornitore di impianti di refrigerazione a subire, nella giornata di ieri, un incidente informatico" (Quotidiano Sanità). It reports no blood products lost.

Why it matters: the second case reached blood storage through a vendor of cooling equipment.

England will vet Palantir's claims

"NHS England has asked to review any claims made by Palantir about the effectiveness of the federated data platform" — HSJ

Why it matters: the review follows concerns from the statistics watchdog, and connects with freedom-of-information replies from trusts counted as benefiting that said they do not use the platform.

Italy and Spain

The president of Italy's regions, after a unanimous vote against the budget: (translated from Italian) "with this budget we risk no longer being able to guarantee coverage of the essential levels of care"; original: "con questa manovra di bilancio rischiamo di non riuscire più a garantire la copertura dei Lea" (Quotidiano Sanità). In Spain, residents' on-call shifts fall to 17 consecutive hours. Catalonia's health minister wants 24-hour shifts gone, but says care (translated from Spanish) "cannot be voluntary, because patients do not fall ill voluntarily"; original: "no puede ser voluntaria, porque los enfermos no se ponen voluntariamente malos" (Redacción Médica).

Medicine concept of the day

PCR correction: when parasites come back, was it a failed cure or a new bite?

A patient in a high-transmission area is treated, and parasites return within a month. Trials decide which happened by comparing parasite genotypes before and after.

"PCR-corrected treatment failure rates are now the preferred end-point in regulatory clinical trials and for monitoring antimalarial drug efficacy." — WHO

KALUMA, the phase 3 trial of ganaplacide-lumefantrine, has just posted one primary "applicable to the non-US submission" and another "applicable to US New Drug Application (NDA) submission" (registry). The company adds a third figure (Novartis).

Day 29 response	New drug	Coartem
Per protocol, corrected (company)	99.2%	96.7%
Corrected, registry	97.4%	94.0%
Uncorrected, registry	85.3%	82.1%

The gap between arms stays similar; the absolute number moves. That number matters because, in an older review's words, "first-line antimalarial treatment policies be changed when a drug's cure rate falls below 90%" (Porter et al.).

The rules disagree on the same samples: "The WHO algorithm identified the fewest recrudescences across all marker combinations, while the 2/3 identified the most." (Cantoreggi et al.). Correction also removes what patients still live through: in Tanzania uncorrected response "ranged from 63.4% in Mkuzi to 85.9% in Mlimba", while corrected response stayed from 97.6% to 100% (Ngasala et al.).

Why it matters: a country's first-line drug can hinge on a genotyping rule applied to a day-28 sample. Which rule gives the true failure rate in high transmission is still unknown: the studies cited here compare methods with each other, with no reference standard.

Worth knowing

References that may not exist. An automated check of 500,000 science, engineering and computing papers: "Affected-paper prevalence rose from 1 in 1,600 (6.3 per 10,000) in 2023 to 1 in 435 (23.0 per 10,000)" by early 2026, with "85.8% precision on masked expert review" (PNAS). This gives journals and anyone mining the literature a rate and a trend, measured outside medicine.

FDA inspections abroad. The FDA is pursuing "inspection parity between domestic and international facilities." The unannounced share rose from 47% to 87% in India and from 19% to 61% in China in a year (STAT). Foreign plants now face more of what domestic ones face.

Brazil's RNA plant. (Translated from Portuguese) "When we talk about RNA, we are talking about technological sovereignty"; original: "Quando falamos em RNA, estamos falando de soberania tecnológica" (Pesquisa FAPESP). The speaker is a Health Ministry official. Capacity is going into two public institutes, with Butantan's plant due in late 2027.

Health systems and policy

CVS Health comes apart

"intends to separate into two independent, publicly traded companies" … "The separation is expected to be completed in the first half of 2028" — CVS Health, SEC filing

Why it matters: this large US combination of insurer, pharmacy-benefit manager, pharmacies and clinics is being undone by its owner. STAT calls it "unraveling decades of deals". MinuteClinic stays with the pharmacies; Oak Street's clinics go with the insurer.

US midterms: new negotiators for Medicaid and the FDA's money

"The power to shape that legislation will fall to senior Democrats," — STAT

Why it matters: "that legislation" is the renewal of the user fees drug companies pay to fund FDA reviews, and Bernie Sanders "will likely lead the Senate's health committee". STAT calls Medicaid and insurance subsidies "likely first targets". Republicans hold control until January, and the nearest dated decision is the 11 December funding bill.

Medicare 2027: a pay cut, a reprieve for monitoring vendors

"we are delaying for two years, to Jan. 1, 2029, the requirement to only allow payment for RPM or RTM services" — CMS

Why it matters: outside contractors keep their route into paid remote monitoring for two more years, since the delayed rule limits payment to services performed by a practice's own staff. The base rate falls 2.31% for clinicians outside qualifying alternative payment models. Separately, drugs bought under 340B, the US hospital discount programme, drop to "average sales price minus 28%" (Becker's), down from plus 6%.

Vaccines built for the Bundibugyo strain

"The World Health Organization on Wednesday approved clinical trials for two new Ebola vaccines," — AFP

Why it matters: the candidates, from Oxford with the Serum Institute of India and from Moderna, target the outbreak's strain, in a response that has confirmed more than ten thousand cases. Results are "expected in early 2027" (UA.News, citing Al Jazeera).

South Sudan: which services stop

"The International Medical Corps (IMC), which supported nearly 100 deliveries a month, ended its services" — MSF

Why it matters: MSF, itself calling for restored funding, gives the list in Malakal: outpatient consultations, laboratory services, mental healthcare and routine immunisation.

AI: using it well

A drug committee as the benchmark. Edison asked its agent to propose the experiments that would de-risk six Incyte targets, then compared them with what the committee requested: "a perfect match or a conceptual match to the actual experiment in 83% of cases" (Edison). It is a vendor case study, and the page does not say who scored the matches.

A structure as the output. "Under our direction, Claude searched protein databases, designed the DNA constructs, optimized the isolation method," and the result is "the first 3D structure of a vault particle found in prokaryotic cells." (Anthropic). This is the company's own account of a wet-lab and cryo-electron microscopy workflow, with people directing it and an output others can check.

Startups and deals

Omics vendors sell scale. Alamar reports a "large-scale 60,000-sample study" with GSK, selection "by UK Biobank to profile 80,000 samples" for a Parkinson's study, and "biopharma customers accounting for the largest portion of our revenue for the first time" (SEC filing). Parse and Nomic plan "100 million single-cell RNA-seq profiles" across "over 150,000" perturbation conditions, with commitments from GSK, Pfizer and Sanofi (GEN). That set is planned, not delivered.

GE HealthCare leads a cath-lab round. Laza "raised up to $160 million" for imaging meant to "increase autonomy, alleviate resource constraints", and the system "is not approved for commercial sale in any geography" (release).

A claim someone can check. Ranking neoantigens, tumour fragments that T cells may recognise, on a shared benchmark: "Halmos placed a validated epitope in its top twenty for all five patients." "48 of the 118 team submissions contained none." (Halmos Labs). These are the company's own figures, with no paper linked.

The base rate. "So far this year, just seven companies raised more than half of all seed- through growth-stage investment." (Crunchbase News). That figure covers the US.

Repos and tools

Kimi K3.1 Pro weights are out. "an open-weight, natively multimodal agentic model" with 2.8 trillion parameters (Hugging Face). The publisher's own table puts it close to Claude Opus 5.5 on agentic coding (65.7 against 66.4) and far behind GPT-6 Astra on its hardest reasoning test (39.4 against 65.8). The licence exempts internal use, which matters to labs that must run models on their own hardware.

Two for working with agents. Horizon "collects, filters, and deduplicates" news into daily briefings under scoring rules you can read. "Worktrunk is a CLI for git worktree management, designed for running AI agents in parallel." (GitHub).

Patents

A Kyushu University application aims at more dyes per tissue section, "increasing the number of fluorescent dyes that can be used simultaneously", unmixed by a trained model behind a liquid-crystal filter (EP 4835446). An Imec application puts wavelength selection into a skin sensor's detectors, "an array of thin-film microcavity detectors" (EP 4834205).

Other frontiers

Three-photon imaging, redesigned. "But the maximum depth at which functional recording has been previously achieved was about 1.2 millimeters." A Rockefeller group now reports "tissue depths of up to ~2 millimeters in mouse cortex and hippocampus", by "delivering fewer but much more energetic laser pulses while maintaining the same average laser power" (optics.org). Neuroscientists get deeper cellular recordings without added laser power.

A photonic chip on a working telescope instrument. "During 2024 and 2025, the PIC was put to the test in the CHARIOT instrument, and it recorded signals from a wide range of stars—including ones fainter than reached by the system it replaced." (Laser Focus World). This is two years of use on the sky, beyond a bench demonstration.

Micrometres from candle wax. "In his experiments, a gap of less than 5 µm was maintained over twelve hours" (Hackaday). A hobby build with paraffin, provided you can hold the temperature. Somewhere a precision-stage catalogue feels a slight draught.

Big tech

Data centres meet the voter: "nearly every relevant local ballot measure opposing data centers won or is winning", and "The final constraint is political, and that may be the most imposing constraint of all." (Stratechery). It bears on where AI capacity can be built at all.

Corners of the web

A post asked how to restore a "vintage" microscope, and the word did not survive the histology techs: "Olympus BH-2 isn't vintage. It's still a workhorse scope used by cytotechs and pathologists every day" (r/Histology). Meanwhile, offered a mixed-model patch, DESeq2's maintainer replied: "I am not adding new features to DESeq2" (Bioconductor), leaving repeated samples per animal to other tools.

People and good examples

Marta Shahbazi, 1985–2026

"demonstrating how this could be used to grow human embryos up to 14 days post fertilisation" … "previous techniques were only capable of sustaining embryo growth until the point of implantation, around seven days after fertilisation." — MRC Laboratory of Molecular Biology

Why it matters: the culture system opened a stretch of human development that was previously out of reach, and groups worldwide adopted it. Shahbazi died on 28 October in a train collision in Spain.

Lonnie Thompson, ice-core pioneer

"Despite being collected more than two decades apart, the cores contained similar oxygen isotope patterns, demonstrating that the climate records preserved within the ice are consistent and reproducible." — Byrd Center

Why it matters: Thompson and Ellen Mosley-Thompson at Ohio State were "pioneering ice core collection on glaciers around the world, including tropical glaciers" (Byrd Center), and this late study tested the record by sampling the same ice cap twice, in 1992 and 2015.

Reads and ideas

Illich against the pursuit. Ten years after Medical Nemesis, Ivan Illich's view was: "Today’s major pathogen is, I suspect, the pursuit of a healthy body" (J Epidemiol Community Health). Of the environmental movement, Illich feared a "new set of experts in the surveillance and management of daily life." (BJGP Life). A sociologist replies: "As with many polemicists, Illich often exaggerates or overstates his case." (Social Science Space). Speculation: more specific tests would not answer this objection to monitoring, since it concerns the pursuit itself.

The speed story from a foreign buyer. A small-biotech CEO on running trials in China through global contractors: "this type of arm’s length model is unlikely to work well in China." (LifeSciVC). The fast review is public; hospitals willing to take on a foreign sponsor are harder to find.

Book of the day

Notes on the Synthesis of Form — Christopher Alexander (1964)

Alexander splits making into two kinds. In craft traditions the people who live with a thing repair it: "It is the fast reaction to single failures, complemented by resistance to all other change" (excerpts, Are.na). Once experts take over, "the selfconscious designer works entirely from the picture in his mind, and this picture is almost always wrong." (Steadman).

A year later he attacked his own decomposition: "For the human mind, the tree is the easiest vehicle for complex thoughts. But the city is not, cannot and must not be a tree." (A City is Not a Tree). By 1971: "I reject the whole idea of design methods as a subject of study" (quoted on LessWrong).

Why it matters: for anyone redesigning a service, it makes the number of hand-offs between a failure and its repair a design variable. The free essay carries most of the idea, and the author would rather you skipped the method.